AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12427202 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin splint (RS)
Number of subjects: 10
Study 12427202 — intervention group
Group type: COMPARATOR
Intervention: Wire-composite splint (WCS)
Number of subjects: 10
Study 12427202 — intervention group
Group type: COMPARATOR
Intervention: Titanium trauma splint (TTS)
Number of subjects: 10
Study 10493325 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist evaluation including medication evaluation, therapeutic recommendations, patient education, and follow-up telemonitoring
Number of subjects: 181
Study 10493325 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist evaluation
Number of subjects: 181
Study 10493325 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 181
Study 7495583 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous warm blood cardioplegia (Group 2 - 58 patients)
Number of subjects: 108
Study 7495583 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cold blood cardioplegia (Group 1 - 50 patients)
Number of subjects: 108
Study 1722704 — intervention group
Group type: EXPERIMENTAL
Intervention: Scatter photocoagulation treatment
Number of subjects: 18
Study 1722704 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 18
Study 7066635 — intervention group
Group type: EXPERIMENTAL
Intervention: ioxaglate
Number of subjects: 20
Study 7066635 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate
Number of subjects: 20
Study 30858146 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight patients (BMI < 18.5 kg/m2)
Number of subjects: 38579
Study 28560519 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-generating minerals (6 ppm of H2 per day)
Number of subjects: 10
Study 28560519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26704611 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 3381
Study 26704611 — intervention group
Group type: COMPARATOR
Intervention: Suppressive acyclovir therapy
Number of subjects: 3381
Study 24465617 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose micronutrient and anti-oxidant supplementation
Number of subjects: 127
Study 24465617 — intervention group
Group type: COMPARATOR
Intervention: Recommended daily allowance (RDA) vitamins
Number of subjects: 127
Study 22647387 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, all-layer suture technique using slowly absorbable monofilament material (two Monoplus loops)
Number of subjects: 80
Study 22647387 — intervention group
Group type: COMPARATOR
Intervention: Interrupted suture technique using rapidly absorbable braided material (Vicryl sutures)
Number of subjects: 80
Study 20637561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 20
Study 20637561 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (HBA)
Number of subjects: 20
Study 18408402 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for breast cancer (clinical breast examination)
Number of subjects: 0
Study 18408402 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for cervix cancer (visual inspection of the cervix after application of 4% acetic acid)
Number of subjects: 0
Study 18408402 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for breast cancer
Number of subjects: 0
Study 18408402 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for cervix cancers
Number of subjects: 0
Study 18408402 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for cervix pre-cancers
Number of subjects: 0
Study 15083365 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled aerobic training for 8 weeks (6 sessions/week, 45 min each at 70-80% max heart rate) followed by a 10-month home-based training program
Number of subjects: 24
Study 15083365 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled aerobic training for 8 weeks
Number of subjects: 24
Study 15083365 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based training program for 10 months
Number of subjects: 24
Study 11786110 — intervention group
Group type: COMPARATOR
Intervention: LdCa (1.25 mmol/L)
Number of subjects: 18
Study 11786110 — intervention group
Group type: EXPERIMENTAL
Intervention: dCaP (1.25 mmol/L for first 2 hours, 1.75 mmol/L for last 2 hours)
Number of subjects: 18
Study 11786110 — intervention group
Group type: COMPARATOR
Intervention: MdCa (1.5 mmol/L)
Number of subjects: 18
Study 11786110 — intervention group
Group type: EXPERIMENTAL
Intervention: dCaP
Number of subjects: 18
Study 9838746 — intervention group
Group type: EXPERIMENTAL
Intervention: Funoran containing chewing gum (FG)
Number of subjects: 15
Study 9838746 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucalyptus extract containing chewing gum (EG)
Number of subjects: 15
Study 9838746 — intervention group
Group type: COMPARATOR
Intervention: Control gum
Number of subjects: 15
Study 7861833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amphotericin B (AmB) at a dose of 0.5 mg/kg/48 h from day + 1 BMT until hemoperipheral recovery (group A)
Number of subjects: 45
Study 7861833 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B) who did not receive prophylactic AmB
Number of subjects: 45
Study 7861833 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amphotericin B (AmB) (group A)
Number of subjects: 45
Study 7861833 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 45
Study 2683457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccine (0.55 microgram active components, administered intermittently over six months)
Number of subjects: 22
Study 2683457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccine (6 or 9 capsules per day)
Number of subjects: 22
Study 2683457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vaccine
Number of subjects: 22
Study 4448869 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontingently warm and rewarding model
Number of subjects: 36
Study 4448869 — intervention group
Group type: COMPARATOR
Intervention: Neutral and nonrewarding model
Number of subjects: 36
Study 4448869 — intervention group
Group type: COMPARATOR
Intervention: No model exposure
Number of subjects: 36
Study 31533750 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified SB (600 mg·kg‐1 over 19.5 h)
Number of subjects: 7
Study 31533750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute SB (300 mg·kg‐1)
Number of subjects: 7
Study 31533750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31533750 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified SB
Number of subjects: 7
Study 31533750 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute SB
Number of subjects: 7
Study 27889845 — intervention group
Group type: EXPERIMENTAL
Intervention: PROGRIP (self-gripping semi re-absorbable mesh)
Number of subjects: 45
Study 27889845 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene (traditional polypropylene mesh)
Number of subjects: 45
Study 26307568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenetic evidence presented by prosecution
Number of subjects: 372
Study 26307568 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric diagnosis of psychopathy presented by prosecution
Number of subjects: 372
Study 26307568 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogenetic evidence presented by defence
Number of subjects: 372
Study 26307568 — intervention group
Group type: COMPARATOR
Intervention: Psychiatric diagnosis of psychopathy presented by defence
Number of subjects: 372
Study 24310987 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal packing (n=86)
Number of subjects: 190
Study 24310987 — intervention group
Group type: COMPARATOR
Intervention: No vaginal packing (n=87)
Number of subjects: 190
Study 22480515 — intervention group
Group type: EXPERIMENTAL
Intervention: SLV-306 (daglutril)
Number of subjects: 13
Study 19353750 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated allograft
Number of subjects: 68
Study 19353750 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 68
Study 19353750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 20084712 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fraction of 8 Gy (SF group)
Number of subjects: 107
Study 20084712 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiotherapy of 40 Gy in 20 fractions (CF group)
Number of subjects: 107
Study 16116682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized fluticasone propionate (FP) 250 mcg twice daily for 10 days
Number of subjects: 168
Study 16116682 — intervention group
Group type: COMPARATOR
Intervention: Nebulized budesonide (BUD) 500 mcg twice daily for 10 days
Number of subjects: 168
Study 16116682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both FP and BUD
Number of subjects: 168
Study 12325104 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapy
Number of subjects: 0
Study 12325104 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 10466475 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine 2.5 mg twice daily (n = 9)
Number of subjects: 24
Study 10466475 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg twice daily (n = 8)
Number of subjects: 24
Study 10466475 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 8647483 — intervention group
Group type: EXPERIMENTAL
Intervention: Women postpartum
Number of subjects: 0
Study 8647483 — intervention group
Group type: COMPARATOR
Intervention: Newborns
Number of subjects: 0
Study 8647483 — intervention group
Group type: EXPERIMENTAL
Intervention: Women postpartum (after 42 weeks of gestation)
Number of subjects: 0
Study 8647483 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns (born after 42 weeks of gestation)
Number of subjects: 0
Study 8647483 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (before 38 weeks of gestation)
Number of subjects: 0
Study 2192585 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril, 25 mg administered orally
Number of subjects: 30
Study 2192585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 526401 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide 300 mg
Number of subjects: 5
Study 526401 — intervention group
Group type: COMPARATOR
Intervention: Labetalol 150 mg
Number of subjects: 5
Study 31000180 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 27
Study 31000180 — intervention group
Group type: EXPERIMENTAL
Intervention: S (‐) amlodipine (2.5 mg)
Number of subjects: 27
Study 26938750 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil OSF 100 mg formulations
Number of subjects: 18
Study 26938750 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil citrate 100 mg tablets
Number of subjects: 18
Study 25870478 — intervention group
Group type: EXPERIMENTAL
Intervention: Early nutrition
Number of subjects: 154
Study 25870478 — intervention group
Group type: COMPARATOR
Intervention: Late nutrition
Number of subjects: 154
Study 23681047 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam suppositories
Number of subjects: 21
Study 23681047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 21624736 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at 3 months after myocardial infarction
Number of subjects: 160
Study 21624736 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at 3 days after myocardial infarction
Number of subjects: 160
Study 21624736 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP measured at 3 months compared to 3 days
Number of subjects: 160
Study 19213575 — intervention group
Group type: EXPERIMENTAL
Intervention: Interscalene continuous infusion of 2% ropivacaine (2 mL/h)
Number of subjects: 40
Study 19213575 — intervention group
Group type: COMPARATOR
Intervention: Subacromial continuous infusion of 2% ropivacaine (2 mL/h)
Number of subjects: 40
Study 16933001 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 130
Study 16933001 — intervention group
Group type: COMPARATOR
Intervention: Prokinetics
Number of subjects: 130
Study 15123230 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (160/4.5 microg, 1 or 2 inhalations; Symbicort Turbuhaler)
Number of subjects: 27
Study 15123230 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (1 inhalation)
Number of subjects: 27
Study 15123230 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (2 inhalations)
Number of subjects: 27
Study 15123230 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (1 or 2 inhalations)
Number of subjects: 27
Study 15123230 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (50/250 microg; Seretide Diskus)
Number of subjects: 27
Study 15123230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 10516704 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated bone marrow donors
Number of subjects: 27
Study 7720476 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg, single intravenous dose)
Number of subjects: 22
Study 7720476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 22
Study 2297461 — intervention group
Group type: COMPARATOR
Intervention: 2 mg oral loperamide (4 doses)
Number of subjects: 19
Study 2297461 — intervention group
Group type: COMPARATOR
Intervention: 16 mg oral loperamide (1 dose)
Number of subjects: 19
Study 2297461 — intervention group
Group type: COMPARATOR
Intervention: 16 mg oral loperamide (2 doses)
Number of subjects: 19
Study 7247321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (NF)
Number of subjects: 123
Study 7247321 — intervention group
Group type: EXPERIMENTAL
Intervention: Methenamine hippurate (MH)
Number of subjects: 123
Study 7247321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylactic urinary tract disinfectant)
Number of subjects: 123
Study 7247321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (NF) and Methenamine hippurate (MH)
Number of subjects: 123
Study 7247321 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 123
Study 30711321 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 114
Study 30711321 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 114
Study 30711321 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine
Number of subjects: 114
Study 30711321 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dressing
Number of subjects: 114
Study 30711321 — intervention group
Group type: COMPARATOR
Intervention: Weekly dressing
Number of subjects: 114
Study 30711321 — intervention group
Group type: COMPARATOR
Intervention: Control (regular pin site care)
Number of subjects: 114
Study 28668770 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 104
Study 28668770 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 104
Study 28668770 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 104
Study 24700581 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release opioid (oxycodone or morphine)
Number of subjects: 20
Study 24700581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21705873 — intervention group
Group type: EXPERIMENTAL
Intervention: CUIDATE group (multidimensional physical therapy program)
Number of subjects: 44
Study 20811491 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (six 2-hour group sessions focused on reducing substance use and sexual risk behavior)
Number of subjects: 1686
Study 20811491 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group (six 2-hour group sessions of videos and discussion of MSM community issues unrelated to substance use, sexual risk, and HIV/AIDS)
Number of subjects: 1686
Study 20811491 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized standard HIV-testing group (received standard HIV counseling and testing)
Number of subjects: 1686
Study 17073863 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 41
Study 17073863 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 41
Study 15860763 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 0
Study 11899582 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week physical training
Number of subjects: 1200
Study 10233317 — intervention group
Group type: EXPERIMENTAL
Intervention: MPD regimen starting with 50% of the minimal phototoxic dose (MPD) with weekly increments of 40%, 30%, 25%, 20%, 15%, 10% and 5% to a maximum of 14.5 J/cm2
Number of subjects: 85
Study 10233317 — intervention group
Group type: COMPARATOR
Intervention: Skin type regimen starting with a fixed dose based on skin type with weekly dose increments of 40%, decreasing to 20% once erythema develops
Number of subjects: 85
Study 10233317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (MPD and skin type regimen)
Number of subjects: 85
Study 10233317 — intervention group
Group type: EXPERIMENTAL
Intervention: MPD regimen
Number of subjects: 85
Study 7723453 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood estimation
Number of subjects: 0
Study 7723453 — intervention group
Group type: COMPARATOR
Intervention: Subject-based approach
Number of subjects: 0
Study 7723453 — intervention group
Group type: COMPARATOR
Intervention: Elimination of time
Number of subjects: 0
Study 7723453 — intervention group
Group type: COMPARATOR
Intervention: Calculation of the mean of available data
Number of subjects: 0
Study 7723453 — intervention group
Group type: COMPARATOR
Intervention: Quality-adjusted survival analysis
Number of subjects: 0
Study 2178759 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 700
Study 2178759 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange for multiple sclerosis
Number of subjects: 700
Study 2178759 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange for thrombotic thrombocytopenic purpura
Number of subjects: 700
Study 2178759 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange for rapidly progressive glomerulonephritis
Number of subjects: 700
Study 6259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetables
Number of subjects: 62
Study 6259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast cereals
Number of subjects: 62
Study 6259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereals and biscuits
Number of subjects: 62
Study 6259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit
Number of subjects: 62
Study 6259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products
Number of subjects: 62
Study 6259925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dried legumes
Number of subjects: 62
Study 6259925 — intervention group
Group type: COMPARATOR
Intervention: Fat
Number of subjects: 62
Study 6259925 — intervention group
Group type: COMPARATOR
Intervention: Protein
Number of subjects: 62
Study 6259925 — intervention group
Group type: COMPARATOR
Intervention: Fiber
Number of subjects: 62
Study 6259925 — intervention group
Group type: COMPARATOR
Intervention: Sugar content
Number of subjects: 62
Study 31795967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine (DP)
Number of subjects: 150
Study 28182820 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Resveratrol (RSVhigh)
Number of subjects: 74
Study 28182820 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg Resveratrol
Number of subjects: 74
Study 28182820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 26104542 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only (RT)
Number of subjects: 198
Study 26104542 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 198
Study 26104542 — intervention group
Group type: COMPARATOR
Intervention: Surgery + Radiotherapy (RT)
Number of subjects: 198
Study 26104542 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete resection
Number of subjects: 198
Study 26104542 — intervention group
Group type: COMPARATOR
Intervention: Partial resection
Number of subjects: 198
Study 26104542 — intervention group
Group type: COMPARATOR
Intervention: Total resection
Number of subjects: 198
Study 24314824 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 78
Study 24314824 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 78
Study 24314824 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 78
Study 24314824 — intervention group
Group type: EXPERIMENTAL
Intervention: Groningen Frailty Indicator (GFI)
Number of subjects: 78
Study 22000728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate tCa concentration of 3.0 mEq/L
Number of subjects: 22
Study 22000728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate tCa concentration of 2.75 mEq/L
Number of subjects: 22
Study 22000728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate tCa concentration of 2.5 mEq/L
Number of subjects: 22
Study 19199349 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary dissection
Number of subjects: 0
Study 19199349 — intervention group
Group type: COMPARATOR
Intervention: No axillary dissection or radiotherapy
Number of subjects: 0
Study 19199349 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary treatment (dissection or radiotherapy)
Number of subjects: 0
Study 17356153 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive movement machine
Number of subjects: 27
Study 15373934 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (4.5 microg)
Number of subjects: 20
Study 15373934 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (500 microg)
Number of subjects: 20
Study 11198486 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dumping
Number of subjects: 44
Study 11198486 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without dumping
Number of subjects: 44